New molecules and biopharmaceuticals enhance patient's immune response against tumors

Published on July 22, 2014 at 6:15 AM · No Comments

Researchers at the University of Arkansas have been awarded $1.5 million from the National Cancer Institute at the National Institutes of Health to develop new molecules and biopharmaceuticals that enhance a patient's immune response against tumors.

The goal of the five-year grant is to help clinicians attack hidden metastatic tumors and prevent cancer recurrence, said David Zaharoff, the principal investigator for the project. Metastasis is the development of secondary malignancy away from the primary site of cancer.

"Metastasis, not the primary tumor, kills about 90 percent of cancer patients," said Zaharoff, an assistant professor of biomedical engineering. "Our work has the potential to significantly reduce this percentage."

Zaharoff refers to breast cancer as an example of the importance of striking at metastasis. The overwhelming majority of breast cancers are detected early; tumors are removed and patients receive chemotherapy, radiotherapy, hormone therapy or a combination, depending on the stage of disease.

Usually, these treatments are successful and the patient is given a clean bill of health, because available diagnostics show no detectable tumors. But in reality, many patients have microscopic, undetectable tumors that have already seeded in the bone, brain or liver.

"This is why, five years after treatment, some patients return to the doctor and complain of headaches or dizziness, only to find they have multiple brain lesions," Zaharoff said. "The cancer vaccines and immunotherapies we are developing have the potential to prevent this recurrence."

For this project, titled "Biopolymer-based strategies for local delivery of cytokine therapeutics," Zaharoff will collaborate with Suresh Kumar, associate professor in the department of chemistry and biochemistry at the University of Arkansas. Zaharoff will focus on delivery systems and biomaterials, while Kumar will focus on protein biochemistry.

"This project is a perfect example of the power of collaboration," Zaharoff said. "Our progress would be significantly slower if it weren't for Suresh and his lab. We have common goals, but diverse expertise, that complement each other very well. Our labs have been working together for a couple years, yet I feel that we have only begun to scratch the surface of what is possible."

Zaharoff works primarily with cytokines, which stimulate the body's immune system to attack a range of cancerous tumors. He has demonstrated success with Interleukin-12 (IL-12), a powerful cytokine that, in a previous study, eradicated bladder tumors in mice when he combined the cytokine with chitosan, a natural polysaccharide that enhanced the delivery of IL-12 and its adherence to tumors.

Zaharoff was the first scientist to co-formulate chitosan and IL-12, a discovery he made while working as a postdoctoral fellow at the Laboratory of Tumor Immunology and Biology at the National Cancer Institute. He transferred his research to the U of A when he accepted an endowed position in 2009 and established the Laboratory of Vaccine and Immunotherapy Delivery.

Zaharoff is holder of the Twenty-First Century Professorship in Biomedical Engineering in the College of Engineering. With previous support from his endowed professorship, the Arkansas Biosciences Institute and the University of Arkansas Women's Giving Circle, he has now received more than $3 million in competitive state and federal grants.

Source:

University of Arkansas

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Researchers develop ADNEX test to help doctors diagnose ovarian cancer, choose best treatment